Pierre Fabre Medicament — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Pierre Fabre Medicament appears in 26 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials26

Recruiting shown6

Roles2

SourceClinicalTrials.gov

Clinical trials

26 shown

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET AlterationsNCT06669117 · lead sponsor · 2024-10-22

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIsNCT06567015 · lead sponsor · 2024-09-17

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion MutationsNCT06043817 · lead sponsor · 2023-09-26

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsNCT04913285 · lead sponsor · 2021-08-04

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyNCT03394365 · lead sponsor · 2017-12-29

An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)NCT06690489 · lead sponsor · 2024-11-22

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of TreatmentNCT06500494 · lead sponsor · 2024-09-10

ACTIVE_NOT_RECRUITING

Treatment Patterns of Neratinib in HER2+ EBC in ChinaNCT05491057 · lead sponsor · 2022-09-30

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With NeratinibNCT05599334 · lead sponsor · 2022-07-05

A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)NCT05546905 · lead sponsor · 2022-06-23

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerNCT05195632 · lead sponsor · 2022-06-02

ACTIVE_NOT_RECRUITING

F17464 in Acute Schizophrenia TrialNCT02151656 · lead sponsor · 2014-06-01

Efficacy and Safety of V0111 Cream on Open Cracked Heel in Diabetic Patients With Polyneuropathy.NCT02045199 · lead sponsor · 2014-02-01

Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerNCT01953003 · lead sponsor · 2013-09-01

Bronchodilator Properties and Safety in AsthmaNCT01951222 · lead sponsor · 2013-09-01

Efficacy and Safety Study of F373280NCT01831856 · lead sponsor · 2013-04-01

Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162NCT01348555 · lead sponsor · 2011-04-01

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast CancerNCT01091168 · lead sponsor · 2009-07-01

Trial of Vinflunine Plus Capecitabine in Advanced Breast CancerNCT01095003 · lead sponsor · 2009-05-01

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast CancerNCT03887130 · lead sponsor · 2007-03-27

A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast CancerNCT02054338 · lead sponsor · 2006-06-01

Oral Vinorelbine as Induction Chemotherapy Followed Concomitant ChemoradiotherapyNCT01839032 · lead sponsor · 2005-05-01

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung CancerNCT00683514 · lead sponsor · 2005-04-01

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)NCT03848052 · collaborator · 2017-10-02

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerNCT03801304 · collaborator · 2019-01-24

A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced DiseaseNCT02730091 · collaborator · 2016-02-24

Drugs studied in this sponsor's trials

11 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Pierre Fabre Medicament as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

capecitabine3

placebo2

vinorelbine2

anastrozole1

atezolizumab1

binimetinib1

docetaxel1

encorafenib1

capecitabine RxCUI 194000 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials placebo RxCUI 8375 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials vinorelbine RxCUI 39541 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials anastrozole RxCUI 84857 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial atezolizumab RxCUI 1792776 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial binimetinib RxCUI 2049122 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial encorafenib RxCUI 2049106 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial letrozole RxCUI 72965 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial neratinib RxCUI 1940643 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor23

collaborator3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.